Dark

Check out our Level2View

CTYX
Connectyx Technologies Holdings Group, Inc. NEW Common Stock
stock OTC

Inactive

Apr 28, 2021

0.1440USD+15.200%(+0.0190)3,508,421

Pre-market

0.00USD-100.000%(-0.13)0

After-hours

0.00USD0.000%(0.00)0

Overview HistoricalExchangesShortsNews

May 25, 2021

09:50AM EDT Curative Biotechnology, Inc. (OTC: CUBT) (Curative Biotech or the Company), a development-stage biomedical company targeting novel treatments for rare diseases, filed its Q1 quarterly reportfor the period ending March 31, 2021. The Q1 report can be viewed in its entirety at: GlobeNewswire Inc

Apr 29, 2021

10:12AM EDT Kapil Bharti, Ph.D.and Dimiter Dimitrov, Ph.D. Join Scientific and Clinical Advisory Board GlobeNewswire Inc

09:30AM EDT Curative Biotechnology, Inc. Announces FINRA Ticker Symbol Change From "CTYX" PR Newswire

Mar 9, 2021

10:25AM EST Biotechnology Company Issues Highlights and Subsequent Events GlobeNewswire Inc

Feb 11, 2021

10:50AM EST Expertise in Clinical Development, Regulatory Affairs and Manufacturing Represented GlobeNewswire Inc

09:45AM EST Connectyx Announces Key Biotech Industry Veterans to Management Team PR Newswire

Feb 4, 2021

11:17AM EST Connectyx Announces Grant of Exclusive Worldwide License from GlobeNewswire Inc

10:12AM EST Institutes of Health for Repurposing Metformin to Treat Degenerative Eye Disease PR Newswire

Nov 23, 2020

10:00AM EST Initial Biotechnology Portfolio Includes Therapies for Glioblastoma and Late Stage Rabies GlobeNewswire Inc

Oct 16, 2020

11:00AM EDT Connectyx Announces Grant of License from National Institutes of GlobeNewswire Inc

Oct 9, 2020

09:30AM EDT Connectyx Technologies Holdings Group, Inc. Announces Definitive GlobeNewswire Inc

Aug 27, 2020

09:30AM EDT Connectyx Technologies Holdings Group, Inc. Announces Strategic GlobeNewswire Inc

Share